Carolyn Sue

Last updated

Carolyn Mary Sue AM is an Australian physician-scientist, professor and research director. She has been the Executive Director of the Kolling Institute of Medical Research since 2019 and is also Director of Neurogenetics at Royal North Shore Hospital, Director of the Centre of Excellence for Parkinson's Disease and Movement Disorders, and Director of the National Centre for Adult Stem Cell Research (Sydney Node). [1] Sue specialises in complex neurogenetic conditions and runs tertiary referral clinics for patients with diseases such as Parkinson's, mitochondrial diseases, and other inherited movement disorders. [1] Her research has identified several previously-unknown mutations that cause neurogenetic disease. [2]

Contents

Education and career

Sue completed a medical degree at the University of New South Wales and a PhD at the University of Sydney in 1997. [1] [3] [4] She then received an NHMRC Neil Hamilton Fairley Postdoctoral Fellowship to conduct post-doctoral studies in the laboratory of Salvatore DiMauro at Columbia University in New York City. [3] In 2000, Sue returned to Sydney to direct her own research laboratory at the Kolling Institute of Medical Research. [3] In 2011, she established the Centre of Excellence for Parkinson's disease and Movement Disorders at Royal North Shore Hospital. [5]

Professor Sue holds multiple titles and was the inaugural Professor in Neurology at Royal North Shore Hospital. She is also a Founding Director of the Australian Mitochondrial Disease Foundation, President-Elect for the Movement Disorder Society of Australia and New Zealand, and Co-Chair of the Education Committee for the International Parkinson's Disease and Movement Disorder Society. [3]

Biomedical research

Sue's research aims to improve our understanding of neurological disorders and develop new treatment options for patients. [1] Due to the Kolling Institute's close proximity and strong collaboration with the hospital, her work is highly translational and her laboratory is able to study cells taken from patients and induced into a stem cell state to elucidate the unique genetic diagnosis for individual patients. [1] This may assist in family planning when patients have a known genetic mutation that causes disease. [1]

Her laboratory currently runs several projects, [1] including:

Sue has published on the potential of mitochondrial donation as a potential strategy to tackle hereditary mitochondrial diseases. [6] Mitochondrial donation allows the replacement of defective mitochondria with healthy mitochondria in an unborn child, with requires the use assisted reproductive technologies to conceive a child from the genetic material of three persons. [6] However, as mitochondrial DNA contributes only to cellular bioenergetics and not any other characteristics of the child, the oocyte donor (i.e., the mitochondria donor) does not contribute to a child's unique genomic identity. [6] In 2022, Maeve's Law was passed by the Australian Parliament to legalise mitochondrial donation. [7] Sue's future work will likely involve preparing and supporting her patients if they choose to undergo the procedure. [8]

Awards and recognition

In 2016, Sue was awarded a Presidential Award by the International Parkinson's Disease and Movement Disorder Society. [9] In 2019, Sue was part of the Queen's Birthday Honours List and awarded a Member of the Order of Australia for significant services to medicine. [1] [9]

Sue is currently the Executive Director of the Kolling Institute of Medical Research, Board Member for the Brain and Mind Centre, and Professor of Neurology at the University of Sydney. She is also Founder and Director of the Centre of Excellence for Parkinson's Disease and Movement Disorders, Director of Neurogenetics, Director of the Mitochondrial Disease Clinic, Director of the Genetic Movement Disorders Clinic, Director of the Hereditary Spastic Paraplegia Clinic, and Director of the Advanced Therapies for Parkinson's Disease Clinic at the Royal North Shore Hospital. [9]

See also

Related Research Articles

Charcot–Marie–Tooth disease Neuromuscular disease

Charcot–Marie–Tooth disease (CMT) is a hereditary motor and sensory neuropathy of the peripheral nervous system characterized by progressive loss of muscle tissue and touch sensation across various parts of the body. This disease is the most commonly inherited neurological disorder affecting about one in 2,500 people. It is named after those who classically described it: the Frenchman Jean-Martin Charcot (1825–1893), his pupil Pierre Marie (1853–1940), and the Briton Howard Henry Tooth (1856–1925).

Anita Elizabeth Harding was an Irish-British neurologist, and Professor of Clinical Neurology at the Institute of Neurology of the University of London. She is known for the discovery with Ian Holt and John Morgan-Hughes of the "first identification of a mitochondrial DNA mutation in human disease and the concept of tissue heteroplasmy of mutant mitochondrial DNA", published in Nature in 1986. In 1985 she established the first neurogenetics research group in the United Kingdom at the UCL Institute of Neurology.

Mitochondrial disease Spontaneously occurring or inherited disorder that involves mitochondrial dysfunction

Mitochondrial disease is a group of disorders caused by mitochondrial dysfunction. Mitochondria are the organelles that generate energy for the cell and are found in every cell of the human body except red blood cells. They convert the energy of food molecules into the ATP that powers most cell functions.

Hereditary spastic paraplegia (HSP) is a group of inherited diseases whose main feature is a progressive gait disorder. The disease presents with progressive stiffness (spasticity) and contraction in the lower limbs. HSP is also known as hereditary spastic paraparesis, familial spastic paraplegia, French settlement disease, Strumpell disease, or Strumpell-Lorrain disease. The symptoms are a result of dysfunction of long axons in the spinal cord. The affected cells are the primary motor neurons; therefore, the disease is an upper motor neuron disease. HSP is not a form of cerebral palsy even though it physically may appear and behave much the same as spastic diplegia. The origin of HSP is different from cerebral palsy. Despite this, some of the same anti-spasticity medications used in spastic cerebral palsy are sometimes used to treat HSP symptoms.

MASA syndrome Medical condition

MASA syndrome is a rare X-linked recessive neurological disorder on the L1 disorder spectrum belonging in the group of hereditary spastic paraplegias a paraplegia known to increase stiffness spasticity in the lower limbs. This syndrome also has two other names, CRASH syndrome and Gareis-Mason syndrome.

Primary lateral sclerosis (PLS) is a very rare neuromuscular disease characterized by progressive muscle weakness in the voluntary muscles. PLS belongs to a group of disorders known as motor neuron diseases. Motor neuron diseases develop when the nerve cells that control voluntary muscle movement degenerate and die, causing weakness in the muscles they control.

The Kolling Institute is located on the grounds of the Royal North Shore Hospital in St Leonards, Sydney Australia. The institute, founded in 1920, is the oldest medical research institute in New South Wales.

MERRF syndrome Medical condition

MERRF syndrome is a mitochondrial disease. It is extremely rare, and has varying degrees of expressivity owing to heteroplasmy. MERRF syndrome affects different parts of the body, particularly the muscles and nervous system. The signs and symptoms of this disorder appear at an early age, generally childhood or adolescence. The causes of MERRF syndrome are difficult to determine, but because it is a mitochondrial disorder, it can be caused by the mutation of nuclear DNA or mitochondrial DNA. The classification of this disease varies from patient to patient, since many individuals do not fall into one specific disease category. The primary features displayed on a person with MERRF include myoclonus, seizures, cerebellar ataxia, myopathy, and ragged red fibers (RRF) on muscle biopsy, leading to the disease's name. Secondary features include dementia, optic atrophy, bilateral deafness, peripheral neuropathy, spasticity, or multiple lipomata. Mitochondrial disorders, including MERRFS, may present at any age.

MRC Mitochondrial Biology Unit

The MRC Mitochondrial Biology Unit is a department of the School of Clinical Medicine at the University of Cambridge, funded through a strategic partnership between the Medical Research Council and the University. It is located at the Addenbrooke’s Hospital / Cambridge Biomedical Campus site in Cambridge, England. The unit is concerned with the study of the mitochondrion, as this organelle has a varied and critical role in many aspects of eukaryotic metabolism and is implicated in many metabolic, degenerative, and age-related human diseases.

Paraplegin

Paraplegin is a protein that in humans is encoded by the SPG7 gene located on chromosome 16.

KIF5A

Kinesin heavy chain isoform 5A is a protein that in humans is encoded by the KIF5A gene.

Mitochondrial replacement therapy (MRT), sometimes called mitochondrial donation, is the replacement of mitochondria in one or more cells to prevent or ameliorate disease. MRT originated as a special form of in vitro fertilisation in which some or all of the future baby's mitochondrial DNA (mtDNA) comes from a third party. This technique is used in cases when mothers carry genes for mitochondrial diseases. The therapy is approved for use in the United Kingdom. A second application is to use autologous mitochondria to replace mitochondria in damaged tissue to restore the tissue to a functional state. This has been used in clinical research in the United States to treat cardiac-compromised newborns.

Kufor–Rakeb syndrome Medical condition

Kufor–Rakeb syndrome (KRS) is an autosomal recessive disorder of juvenile onset also known as Parkinson disease-9 (PARK9). It is named after Kufr Rakeb in Irbid, Jordan. Kufor–Rakeb syndrome was first identified in this region in Jordan with a Jordanian couple's 5 children who had rigidity, mask-like face, and bradykinesia. The disease was first described in 1994 by Najim Al-Din et al. The OMIM number is 606693.

Joseph Jankovic American neurologist

Joseph Jankovic is an American neurologist who is a professor in neurology at Baylor College of Medicine in Houston, Texas. He is the Distinguished Chair in Movement Disorders and founder and director of the Parkinson's Disease Center and Movement Disorders Clinic.

David Charles is an American neurologist, professor and vice-chair of neurology, and the medical director of Telehealth at Vanderbilt University Medical Center.

Aleksandra Filipovska is a Senior Research Fellow at the University of Western Australia, heading a research group at the Harry Perkins Institute of Medical Research. Specializing in biochemistry and molecular biology, she has made contributions to the understanding of human mitochondrial genetics in health and disease.

Mitohondrial optic neuropathies are a heterogenous group of disorders that present with visual disturbances resultant from mitochondrial dysfunction within the anatomy of the Retinal Ganglion Cells (RGC), optic nerve, optic chiasm, and optic tract. These disturbances are multifactorial, their aetiology consisting of metabolic and/or structural damage as a consequence of genetic mutations, environmental stressors, or both. The three most common neuro-ophthalmic abnormalities seen in mitochondrial disorders are bilateral optic neuropathy, ophthalmoplegia with ptosis, and pigmentary retinopathy.

Bionics Institute

The Bionics Institute of Australia is a biomedical research institute focusing on medical bionics that creates, designs, evaluates and improves bionic devices that interface with the human body to restore impaired sensory or other nervous system and bodily functions. The Bionics Institute is located in Melbourne, Australia.

Sir Douglass Matthew Turnbull is Professor of Neurology at Newcastle University, an Honorary Consultant Neurologist at Newcastle upon Tyne Hospitals NHS Foundation Trust and a director of the Wellcome Trust Centre for Mitochondrial Research.

Professor Patrick Francis Chinnery FRCP FRCPath FMedSci is a neurologist, clinician scientist, and Wellcome Trust Principal Research Fellow based in the Medical Research Council Mitochondrial Biology Unit and the University of Cambridge, where he is also Professor of Neurology and Head of the Department of Clinical Neurosciences.

References

  1. 1 2 3 4 5 6 7 8 "Neurogenetics". kollinginstitute.org.au. Retrieved 2022-04-07.
  2. "Professor Carolyn Sue: Being a scientist is in the DNA of every clinician and how to build a research question (2019)". AAHMS - Australian Academy of Health and Medical Sciences. Retrieved 2022-04-07.
  3. 1 2 3 4 "Staff Profile". The University of Sydney. Retrieved 2022-04-07.
  4. Sue, Carolyn Mary (1996). "Diversity of phenotypic expression of patients with Melas 3243 point mutation". University of Sydney Library. Retrieved 2022-04-08.
  5. "Professor Carolyn Sue: Being a scientist is in the DNA of every clinician and how to build a research question (2019)". AAHMS - Australian Academy of Health and Medical Sciences. Retrieved 2022-04-07.
  6. 1 2 3 Dziadek, Marie A; Sue, Carolyn M (2021-10-31). "Mitochondrial donation: is Australia ready?". Medical Journal of Australia. 216 (3): 118–121. doi:10.5694/mja2.51309. ISSN   0025-729X.
  7. "'Maeve's Law' to legalise mitochondrial donation through IVF passes Senate". ABC News. 2022-03-31. Retrieved 2022-04-07.
  8. "Australia to introduce ground breaking technology to target debilitating Mito disease". kollinginstitute.org.au. Retrieved 2022-04-07.
  9. 1 2 3 "Professor Carolyn Mary SUE". honours.pmc.gov.au. Retrieved 2022-04-07.